RECORDED WEBINARS

Beginning Date

03/10/20

Ending Date

03/10/21

1.0

credits

Target Audience:

This educational program is targeted at physicians and other healthcare providers who specialize in the management of patients with CLD.

Goal Statement:

Topic-specific webinar presented by a Chronic Liver Disease faculty member who will review and discuss challenging cases in CLD.

Learning Objectives:

Upon completion of this activity, participants should be able to:

•	Describe current guidelines and management recommendations for patients with chronic liver disease
•	Utilizing current therapies, optimize treatment results for patients with chronic liver disease
•	Identify new therapeutic advances and assess their potential impact on clinical practice

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

All individuals in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation have no relationships to disclose.

Learner Assurance Statement:

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of individuals who control activity content and who have significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those individuals with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Accredited by

Provided by

This activity is supported by an educational grant from AbbVie Inc. and Mallinckrodt Pharmaceuticals.

The Chronic Liver Disease Foundation (CLDF) recognizes the important role of the GI fellow in the current and future management of patients with chronic liver disorders. As most of their training is focused on gastroenterology, the CLDF hosted the second annual Liver Summit for GI Fellows in Chicago on August 9th and 10th, 2019. The meeting was designed for third-year GI Fellows nominated by the CLDF Centers of Educational Expertise and fellowship directors.

The Summit brought together approximately sixty third-year fellows who were interested in hepatology. In addition to state-of-the-art disease and management lectures, the program delivered important clinical practice management lectures that provided the fellows with insight into community and academic practices today and when they leave their fellowship.

The following webinars were presented by CLDF faculty to reinforce key learnings from the conference & have been recorded for additional viewers to receive CME credits.

RECORDED WEBINARS

NASH: Current Approach and When Will New Treatment Options Be Available?

Speaker

Zobair M. Younossi MD, MPH, FACG, AGAF, FAASLD

Professor and Chairman, Department of Medicine, Inova Fairfax Medical Campus
Chairman (Acting), Clinical Research, Inova Health System
Falls Church, VA

DISCLOSURES

Research Support: BMS, Gilead, Intercept.

Consultant: BMS, Gilead, Intercept, NovoNordisk, Siemens, Terns, Viking.

Complications of Cirrhosis

Speaker

Steven Flamm, MD, FAASLD, FACG

Chief of Hepatology and Liver Transplantation Program
Professor of Medicine and Surgery
Northwestern Feinberg School of Medicine
Chicago, IL

DISCLOSURES

Consultant: Intercept, Salix.

Hepatitis C: Screening, Barriers and Access to Therapy

Speaker

Robert S. Brown, Jr., MD, MPH

Gladys and Roland Professor of Medicine
Vice Chair, Mentorship and Academic Development
Clinical Chief, Division of Gastroenterology & Hepatology
Weill Cornell Medical College
New York, NY

DISCLOSURES

Research Support: Intercept.

Consultant: Dova, Intercept, Shionogi.

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments

Speaker

David E. Bernstein, MD, FAASLD, AGAF, FACP, FACG

Vice Chairman of Medicine for Clinical Trials
Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases
Northwell Health System
Professor of Medicine and Education Science
Zucker School of Medicine at Hofstra/Northwell

DISCLOSURES

Research Support: CymaBay, Genfit, Gilead, NovoNordisk, Pfizer.

Consultant: Dova, Gilead, Intercept.

Speakers Bureau: Intercept.